| Name | Title | Contact Details |
|---|
OrthoTennessee provides the finest orthopedic clinics in East Tennessee, improving lives through patient-centered care, orthotics, therapy and imaging.
Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate`s product candidate, CMP-001, is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body`s innate immune system to attack tumors in combination with other therapies.
Walking Fish Therapeutics, Inc. is a privately held biotechnology company discovering and developing innovative therapeutics that harness the power of B cells as protein factories and immune modulators. Walking Fish has created a broad technology platform addressing enzyme replacement therapies, oncology, autoimmune disease, and recombinant antibody production. The company`s first program, WFX-001, employs B cells as protein factories to generate a deficient enzyme in Fabry disease. Founded in 2019 by Lewis (Rusty) Williams, MD, PhD, the former CSO of Chiron, co-founder of Cor Therapeutics and founder and Chief Executive Officer of Five Prime Therapeutics, the company has assembled a diverse and experienced team of scientists and business leaders who are committed to bringing life-changing and life-saving therapeutics to patients worldwide.
Family medicine, primary care, and dental service provider for the underserved and uninsured communities of Pinellas County.
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOLâ„¢), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.